Uniqure NV
NASDAQ:QURE
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.78
10.12
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Uniqure NV
Uniqure NV
Free Cash Flow
Uniqure NV
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Uniqure NV
NASDAQ:QURE
|
Free Cash Flow
-$184.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-13%
|
|
|
Pharming Group NV
AEX:PHARM
|
Free Cash Flow
-$540k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
28%
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Free Cash Flow
-€34.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
argenx SE
XBRU:ARGX
|
Free Cash Flow
-$325.2m
|
CAGR 3-Years
18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merus NV
NASDAQ:MRUS
|
Free Cash Flow
-$157.3m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Free Cash Flow
-$39.7m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Uniqure NV
Glance View
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
See Also
What is Uniqure NV's Free Cash Flow?
Free Cash Flow
-184.8m
USD
Based on the financial report for Sep 30, 2024, Uniqure NV's Free Cash Flow amounts to -184.8m USD.
What is Uniqure NV's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-13%
Over the last year, the Free Cash Flow growth was -15%.
You don't have any saved screeners yet
